The Market Crashed and Cannabis Investors Had No Way to Hedge. That’s Not a Bug — It’s the Whole Problem.

When President Trump’s Liberation Day tariff announcement hit markets on April 2nd, investors across most beaten-down sectors had options. They could rotate into defensive positions. They could short a sector index. They could buy puts on an ETF. They could, in the language of Wall Street, manage their risk.

Cannabis investors had none of those. Not one.

That asymmetry — invisible in good times, brutal in bad ones — is one of the more underappreciated structural problems in an industry that has spent the last five years accumulating them.

The Index That’s Already Down 94%

The Global Cannabis Stock Index, which has tracked publicly-traded cannabis companies since 2012, sat at 100 at the end of that year. It currently sits at 5.26. That’s not a misprint. The index has declined 88.2% since its peak in late 2020 and over 94% from its 2012 baseline. In 2026 alone — before Liberation Day — it was already down 20.2%.

That context matters when the broader market craters, because cannabis stocks were starting the rout from a position of profound weakness, not merely from a high valuation. Most blue-chip tech names that got hammered in the tariff selloff had years of gains to give back. Cannabis stocks were down 88% from their highs before April 2nd even happened.

And still, there was no hedge. The standard playbook — options, futures, inverse ETFs, sector rotation — simply does not exist for most U.S. cannabis operators. American cannabis companies trade on OTC markets, not on major U.S. exchanges. The reason is federal illegality. And because they’re OTC, they’re excluded from most institutional investment frameworks, most ETF baskets with meaningful assets under management, and every standard hedging instrument that requires exchange listing.

When the rest of the market braced for impact, cannabis investors could only watch.

The Debt Wall Hasn’t Moved

The market volatility lands at the worst possible time structurally. By most estimates, approximately $3 billion in debt will come due for major U.S. cannabis operators by the end of 2026. A handful of companies have already transferred control to their creditors: 4Front Ventures, Ayr Wellness, The Cannabist Company, Gold Flora, MedMen, Schwazze, and Tilt Holdings have all seen debt holders gain effective ownership in one form or another.

Curaleaf, the largest cannabis operator by revenue, extended some of its debt earlier this year — but the total debt load remains among the highest in the sector. New Cannabis Ventures founder Alan Brochstein noted this week that “others will be forced to refinance their debt,” and that a number of MSOs face “massive” refinancing challenges if rescheduling doesn’t materialize.

Here’s the structural trap: refinancing cannabis debt is not like refinancing a tech company’s notes. Cannabis companies can’t go to the bond markets the way conventional companies can. They can’t approach most institutional lenders. They can’t use SBA programs. The SAFE Banking Act — which would allow banks to service cannabis businesses without federal penalty — has still not passed. The CLIMB Act, which would have created SBA-equivalent lending mechanisms for cannabis operators, has not passed either.

So when debt comes due in this environment — with cannabis stocks at generational lows, tariff uncertainty rattling investor confidence, and broader capital markets on edge — the refinancing options are not just limited. In some cases, they are effectively nonexistent.

280E Is Still Running in the Background

Layered on top of the capital structure problem is the tax problem. Section 280E of the Internal Revenue Code bars cannabis businesses from deducting ordinary business expenses because they’re still federally classified as Schedule I drug traffickers. Every dollar spent on rent, payroll, utilities, and marketing is taxed as gross income above cost of goods sold.

According to MJ Biz Daily, using Headset modeling, 280E creates between $400,000 and more than $800,000 in extra tax liability per store per year. That’s not a rounding error. That’s capital that cannot go toward debt service, toward capital expenditure, or toward surviving a tariff-driven recession.

The Trump administration issued an executive order in December signaling interest in rescheduling, which would effectively eliminate 280E. But there is no timeline. The DEA’s review is ongoing and the process has slipped from 2024 to 2025 to now, apparently, 2026-or-later. Cannabis operators are paying the 280E tax today, tomorrow, and every quarter until rescheduling is finalized — and they’re doing it while their stocks are at 94% below peak and their debt matures into a frozen capital market.

What the Tariff Moment Actually Reveals

The tariff crash is, in one sense, a side issue for cannabis. Operators don’t need to import or export across the borders that tariffs target — cannabis is still federally illegal, so the supply chain is entirely domestic. My own analysis of tariff effects on the industry, published last week, focused on the indirect hit: hardware and packaging sourced from China that gets more expensive with each tariff round, squeezing already-compressed margins.

But the tariff crash is also a stress test of something more fundamental: how an industry performs under external pressure when it lacks the conventional tools to respond.

And the answer, right now, is: badly.

Whitney Economics revised its 2026 U.S. cannabis market forecast to $30.5 billion — a projected 4.9% rebound after 2025’s historic first-ever annual revenue decline. But Whitney’s chief economist Beau Whitney also acknowledged that forecast accuracy dropped from mid-to-high 90% to 85% in 2025, largely because price deflation was more severe than the models anticipated. He’s now revised the models to account for pricing compression more aggressively.

The growth story for cannabis is still plausible. New York, Ohio, and other recently expanded markets will eventually deliver on their sales potential. But the path from here to there runs through a capital structure that is acutely fragile, at a moment when external shocks are arriving and the hedging toolkit is empty.

Who Benefits From the Wreckage

There is one constituency that benefits from this dynamic: distressed asset buyers. When MSOs can’t refinance, when creditors take control, when OTC stocks fall to penny territory — well-capitalized acquirers can buy cannabis infrastructure at fire-sale prices. Dispensary networks, cultivation facilities, licenses in limited-license states: all of it reprices down.

That’s not a conspiracy theory. It’s basic distressed investing. The same dynamic played out in cannabis banking: operators were forced into private lending arrangements at punishing interest rates precisely because standard banking was unavailable. The structural isolation of the industry didn’t prevent capital from flowing in. It just ensured that capital flowed in on terms that were heavily tilted toward the lender.

The tariff moment didn’t create this problem. It just illuminated it, again, with the lights up.

For investors still holding cannabis positions, the honest answer is that there is no elegant exit or hedge available. For operators, the calculus is the same as it’s been for two years: survive until rescheduling, manage debt as creatively as possible, and hope the structural barriers come down before the debt wall arrives.

The storm, as New Cannabis Ventures put it this week, will hopefully pass over. But hoping is not a hedging strategy.